These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 31936661)

  • 1. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.
    Yang PM; Lin LS; Liu TP
    Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.
    Gao J; Chen H; Yu Y; Song J; Song H; Su X; Li W; Tong X; Qian W; Wang H; Dai J; Guo Y
    Biomaterials; 2013 Dec; 34(38):10084-98. PubMed ID: 24060417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase.
    Lin JC; Liu TP; Chen YB; Huang TS; Chen TY; Yang PM
    Toxicol Appl Pharmacol; 2023 Jul; 471():116568. PubMed ID: 37245555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of osalmid metabolic profile and active metabolites with anti-tumor activity in human hepatocellular carcinoma cells.
    Wu Z; Zhan Y; Wang L; Tong J; Zhang L; Lin M; Jin X; Jiang L; Lou Y; Qiu Y
    Biomed Pharmacother; 2020 Oct; 130():110556. PubMed ID: 32763815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells.
    Chu H; Wu C; Zhao Q; Sun R; Yang K; Zhao B; Liu Y; Liang Z; Zhong S; Zhang L; Zhang Y
    Carcinogenesis; 2021 May; 42(5):753-761. PubMed ID: 33677528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib.
    Fondevila F; Méndez-Blanco C; Fernández-Palanca P; Payo-Serafín T; van Pelt J; Verslype C; González-Gallego J; Mauriz JL
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
    He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
    Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy.
    Zhan Y; Jiang L; Jin X; Ying S; Wu Z; Wang L; Yu W; Tong J; Zhang L; Lou Y; Qiu Y
    Biomed Pharmacother; 2021 Jan; 133():110996. PubMed ID: 33227712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
    Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
    J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
    Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF
    Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
    Chen P; Wu JN; Shu Y; Jiang HG; Zhao XH; Qian H; Chen K; Lan T; Chen CG; Li J
    Clin Sci (Lond); 2018 Jul; 132(13):1417-1433. PubMed ID: 29853661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
    Lu S; Yao Y; Xu G; Zhou C; Zhang Y; Sun J; Jiang R; Shao Q; Chen Y
    Cell Death Dis; 2018 May; 9(6):646. PubMed ID: 29844385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
    Lai YL; Wang KH; Hsieh HP; Yen WC
    J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
    Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
    Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
    Xue ST; Li K; Gao Y; Zhao LY; Gao Y; Yi H; Jiang JD; Li ZR
    Autophagy; 2020 Oct; 16(10):1823-1837. PubMed ID: 31986961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.